Efavirenz is an FDA-approved medication used for the treatment and prevention of HIV-1 infection. The drug is a non-nucleoside reverse transcriptase inhibitor (NNRTI). Like most other NNRTI agents, it is commonly combined with other agents with different + some more technical info: Efavirenz binds an allosteric pocket of HIV-1 reverse transcriptase, inducing conformational changes that noncompetitively inhibit DNA polymerization. The active substance is the (S)-enantiomer with the chemical name (S)-6-chloro-4-(cyclopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-2H-3,1-benzoxazin-2-one, molecular formula C14H9ClF3NO2 and molecular weight 315.68 g/mol. It is highly lipophilic with low aqueous solubility, exhibits high plasma protein binding around 99.5 percent, and undergoes extensive hepatic metabolism primarily via CYP2B6 and to a lesser extent CYP3A4 to hydroxylated metabolites such as 8-hydroxyefavirenz. The long terminal elimination half-life typically supports once-daily oral dosing, commonly 600 mg, and formulation development must address photo- and oxidative stability as well as solubility enhancement strategies for consistent bioavailability.
Parent: Efavirenz
Parent: Efavirenz
Parent: Efavirenz
Parent: Efavirenz
Parent: Efavirenz
Parent: Efavirenz
Parent: Efavirenz
Parent: Efavirenz
Parent: Efavirenz
Parent: Efavirenz
Parent: Efavirenz
Efavirenz API impurity profiles center on predictable oxidative and process-related species; common related compounds include hydroxylated metabolites and degradants such as 8-hydroxyefavirenz and 7-hydroxyefavirenz, N-oxide derivatives, deschloro analogs and residual process intermediates bearing the cyclopropyl-ethynyl moiety. Typical batch data and internal specifications control individual known impurities in the range of below 0.2 to 0.3 percent for the major hydroxylated impurities, below 0.05 to 0.1 percent for N-oxide and deschloro species, and residual intermediates below 0.1 percent. Unspecified individual impurities are routinely limited to below 0.1 percent and total impurities are commonly limited to under 0.5 to 1.0 percent depending on the regulatory filing and product presentation. Identification and quantification are performed by validated HPLC or LC-MS methods with forced-degradation studies to establish degradation pathways and monitor relevant degradants.
Efavirenz is used as part of antiretroviral therapy to treat and help prevent HIV-1 infection, typically combined with other antiretroviral agents to form an effective regimen that suppresses viral replication.
The most common side effects are central nervous system related, including dizziness, vivid dreams, insomnia, and sometimes mood changes, which often occur early in therapy and may diminish over several weeks.
Efavirenz is often taken at night to reduce the impact of central nervous system side effects such as dizziness and vivid dreams; bedtime dosing can improve tolerability without compromising efficacy.
A commonly known brand name for efavirenz is Sustiva, though it is also available in generic formulations and in fixed dose combinations with other antiretroviral agents.
